- Home
- BCAB vs OCCI Comparison
BCAB vs OCCI Comparison
Compare BCAB & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAB | OCCI |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 139.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAB | OCCI |
|---|---|---|
| Price | $0.78 | $4.73 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 115.8K |
| Earning Date | 11-13-2025 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $5.47 |
| 52 Week High | $1.43 | $10.15 |
Technical Indicators
Market Signals| Indicator | BCAB | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 46.20 |
| Support Level | $0.63 | $4.50 |
| Resistance Level | $0.84 | $4.82 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 60.89 | 40.68 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.